Technology evaluation: NeuroVax, Immune Response Corp.
The Immune Response Corp is developing NeuroVax, a combination vaccine of three T-cell receptor peptides (BV5S2, BV6S5 and BV13S1) in incomplete Freund's adjuvant, as a potential treatment for multiple sclerosis. The vaccine is currently undergoing phase II clinical trials.